Jun 26, 2020
Portage Announces Results of Annual Meeting; Private Placement Update; Corporate Update
Jun 16, 2020
Portage Raises More Than US$6.7 Million Through Non-Brokered Private Placement; Temporary Symbol Change on OTC Markets
Jun 03, 2020
Portage Announces Share Consolidation (Reverse Split) Effective Date
May 25, 2020
Portage Announces Non-Brokered Private Placement
May 12, 2020
Portage is pleased to announce the appointment of Allan L. Shaw as CFO
May 11, 2020
Portage Makes Additional Investment in Stimunity S.A.S, a Paris-Based Cancer Immunotherapy Company.
May 05, 2020
Portage makes an additional investment in Saugatuck therapeutics after achieving proof of concept
Apr 16, 2020
Portage Announces Cease Trade Order Revoked; Update on Impact of COVID-19 on Operations
Apr 15, 2020
Portage provides update on portfolio company, Intensity Therapeutics, Inc.
Mar 13, 2020
Portage Announces Filing of 3rd Quarter Financial Statements and Provides Update on CTO Revocation Application and OTC Trading
Jan 30, 2020
Portage Announces Further Subscription of US$950,000 in Convertible Loan Notes to iOx Therapeutics and Provides Update on CTO Revocation Application
Dec 31, 2019
Portage Announces Filing of Financial Statements and Accompanying MD&A and Provides Company Operations Updates
Nov 27, 2019
Portage Granted Extension by CSE to Cure Default; Comments on OTC Trading and Provides Audit Update
Oct 31, 2019
Portage provides default status report
Aug 26, 2019
Portage Provides Default Status Report
Jul 31, 2019
Portage Confirms Delay in Annual Filings; Expects Issuance of Cease Trade Order
Jul 26, 2019
Portage Announces Filing of Application for Management Cease Trade Order
Jul 11, 2019
Portage Announces Increase in Holdings of Portfolio Company, Intensity Therapeutics With Positive Business, Regulatory, & Clinical Updates
May 06, 2019
Portage Announces Change of CEO
Mar 25, 2019
Portage makes additional investment in Stimunity S.A, a Paris-based cancer immunotherapy company.